Go Mediaction

Main Menu

  • Home
  • Medical field
  • Prescription drugs
  • Drug discovery
  • Medical diagnosis

Go Mediaction

Header Banner

Go Mediaction

  • Home
  • Medical field
  • Prescription drugs
  • Drug discovery
  • Medical diagnosis
Drug discovery
Home›Drug discovery›Charles River and Valo enter AI-enabled drug discovery pact

Charles River and Valo enter AI-enabled drug discovery pact

By Deborah A. Gray
January 19, 2022
0
0

Charles River Laboratories and Valo Health, LLC, a technology company that uses human-centered data and artificial intelligence (AI)-powered calculations to transform drug discovery and development process, have formed a multi-year strategic partnership. This agreement will combine Valo’s Opal computing platform with Charles River’s drug discovery and development capabilities to deliver a transformative new AI-based drug discovery and development platform.

Valo and Charles River have partnered to create enhanced drug discovery solutions that aim to transform the entire preclinical drug discovery process. The companies aim to create and deliver offerings that produce preclinical assets with key performance characteristics optimized for customer preferences.

The partnership will use Valo’s Opal platform for the development of small molecules, which relies on a “closed loop” silicone -experimental platform that rapidly iterates using program data to identify new compounds and leverages Charles River’s discovery optimization capabilities, including medical chemistry , ADME, biology, pharmacology , and finally safety tests and INDIANA submission.

The combined offering will launch in the first half of 2022 and will be available exclusively from Charles River.

“Our collaboration with Valo is another step we are taking towards accelerating drug discovery and development. By leveraging disruptive AI-powered tools like Opal, we can help our customers advance their discoveries to the clinic faster,” said Birgit Girshick, Executive Vice President and Chief Operating Officer, Charles River

“We are thrilled to partner with Charles River to create these enterprise solutions and deliver them to customers. We see this as a significant opportunity to help drive change in the industry and have a meaningful impact to get better medicines to patients faster – leveraging each of Valo’s and Charles River’s unique capabilities. said David Berry, MD, PhD, Founder and CEO of Valo Health.

Tagsdrug discovery

Categories

  • Drug discovery
  • Medical diagnosis
  • Medical field
  • Prescription drugs

Recent Posts

  • Drug Discovery Informatics Market growth opportunities to be exploited
  • key vendors, trends, analysis, segmentation, forecast to 2029 – Designer Women
  • Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report 2022 – ResearchAndMarkets.com
  • PROBE AND ACT ON PRESCRIPTION DRUGS ABUSE
  • Prescription Drug Consumption Market Size, Share and Forecast to 2028 | Pfizer, Roche, Sanofi, Johnson & Johnson, Merck & Co. (MSD) – Designer Women

Archives

  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • November 2020
  • September 2020
  • May 2020
  • March 2020
  • September 2019
  • May 2019
  • August 2018
  • December 2013
  • Privacy Policy
  • Terms and Conditions